Baker Bros. Advisors LP Sage Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $2.5 Million - $4.23 Million	-236,191 Reduced 58.0%	171,026 $1.86 Million
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $7.58 Million - $11 Million	407,217 New	407,217 $7.63 Million
Q4 2018 Feb 13, 2019	SELL	$81.94 - $139.71 $46.5 Million - $79.3 Million	-567,497 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $6.33 Million - $7.74 Million	-45,803 Reduced 7.47%	567,497 $80.2 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $4.71 Million - $5.89 Million	-33,528 Reduced 5.18%	613,300 $96 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $4.61 Million - $5.83 Million	30,314 Added 4.92%	646,828 $104 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $12.8 Million - $35.3 Million	211,029 Added 52.04%	616,514 $102 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $24.9 Million - $35.9 Million	405,485	405,485 $25.3 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.